Market players are focusing on extending their market worldwide together with bringing an expanded product portfolio to attain an edge over the competitors.

DUBAI, UAE / ACCESSWIRE / November 18, 2020 / The pet preforms market is expected to expand at a CAGR of 3.8% during, 2020-2030. According to Future Market Insights (FMI) expansion prospects to outgrowth particularly with sectors taking measures to decrease the harm done to ascertain highest environmental safety. Major players in the beverage packaging sector are updating the production processes and changing over to recycling programs.

"PET preforms market players are engaged in r&d activities for material recyclability to remain relevant due to implementation of regulations to limit dependence on plastics for packaging." concludes the FMI analyst.

Request a report sample to gain comprehensive market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-3676

PET Preforms Market – Key Highlights

North America to remain the lucrative, reflecting a CAGR of 3.8% over the forecast period.
500 ml to 1000 ml PET preforms remains the popular capacity type segment in the global market.
Alaska/Bericap/Obrist Neck Type remains extensively utilized and thus reflecting the highest growth, followed by PCO/BPF neck type preforms segment.
Beverages to reflect highest market value throughout the forecast period.

PET Preforms Market – Drivers

Growth of the ready-to-drink (RTD) market is encouraging the market expansion of PET preforms.
Rise in consumption of water through Bottles are projected to fuel demand for PET preforms.
Increasing significance for sustainable packaging solutions along with recyclable materials is boosting the market growth.

PET Preforms Market – Restraints

Increasing demand for banning single use plastic by several NGOs, environmentalists, and governments is hurting the growth of the market.
Availability of alternative packaging forms to limit the harmful impact of plastic can hinder market growth.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-3676

COVID-19 Impact on the Market

The PET preforms market is foreseeing a significant drop in demand due to COVID-19 led lockdowns all over the world. Shortage of raw materials, supply chain disruptions, and absence of skilled workers and labors from plants have been few factors that impacted the market. However, the PET preforms demand will foresee significant expansion in the 1st quarter of 2021, as production activities recommence and PET preforms demand from end user sectors reinstates to normal.

Competitive Landscape

Major players identified in the PET preforms market are Plastipak Holdings, Inc., ALPLA Werke Alwin Lehner GmbH & Co KG , Resilux NV, RETAL Industries Ltd., Taiwan Hon Chuan Enterprises Co., Ltd., Societe Generale Des Techniques (SGT), Manjushree Technopack Limited Co., Zhongfu Enterprise Co Ltd., Indorama Ventures Public Co., Ltd. and Logoplaste UK Ltd.

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/3676

About the Study

The study offers readers a comprehensive assessment of the PET preforms market. Global, regional and national-level analysis of the latest trends influencing the market is covered in this FMI report. The study provides insights according to capacity (Up to 500 ml, 500 ml to 1000 ml, 1000 ml to 2000 ml, and more than 2000 ml), neck type (ROPP/BPV, PCO/BPF, Alaska/Bericap/Obrist, and others), end use (beverages {bottled water, carbonated drinks, RTD Tea & Coffee, juice, sports drinks, other soft drinks, and alcoholic drinks}, food, personal care, pharmaceuticals, home care, and others) across key regions (North America, Latin America, Europe, China, Asia Pacific, Middle East & Africa).

Explore FMI's Coverage of the Packaging Industry

Recycled PET Market: Get insights on the recycled PET market through FMI's report covering detailed quantitative and qualitative analysis for projection period 2019 – 2029.

PET Syrup Bottle Market: FMI's exhaustive study on the global PET syrup bottle market covers the latest trends, innovations, key players, and popular strategies for the period 2019 – 2029.

PET Jars Market: Obtain detailed analysis on the PET jars market through FMI's report covering competitive analysis, key regions, and segmental analysis for 2019 – 2029.

About Future Market Insights

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/pet-preforms-market
Press Release Source: https://www.futuremarketinsights.com/press-release/pet-preforms-market

SOURCE: Future Market Insights

ReleaseID: 617288

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

LONDON, UK / ACCESSWIRE / November 18, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, today announces that it has entered into a convertible loan note financing facility (the "Facility") with Mint Capital Limited ("Mint Capital") pursuant to which it has conditionally agreed to issue up to £60 million in aggregate principal amount of convertible unsecured loan notes (the "Convertible Loan Notes") to Mint Capital.

Mint Capital is a Bahamas-based investment management company which specialises in providing growth capital to companies around the world.

The Facility will be made available to the Company subject to certain conditions being met. After the issue of the first tranche of £12 million in principal amount of Convertible Loan Notes, use of the Facility will be solely at the discretion of the Company. Further details about the terms and conditions of the Convertible Loan Notes are set out below under "Further details of the Convertible Loan Notes".

The Facility will allow Hemogenyx Pharmaceuticals to accelerate and broaden its development pipeline of novel therapies and treatments for blood cancers and viral diseases. It will also strengthen the Company's negotiating position with both existing and future partners. Further details of the intended use of proceeds are set out below under "Use of proceeds".

The issue of the Convertible Loan Notes is subject to, amongst other things, the Company obtaining shareholder approval to grant the Company's directors (the "Directors") the necessary authorities to issue the Convertible Loan Notes and the Company having published a prospectus approved by the U.K. Financial Conduct Authority (the "FCA").

The Company's CEO, Dr Vladislav Sandler, commented, "Our various product candidates have shown great results in our laboratory research and testing, and the Company is poised to move our product candidates into proof of concept and clinical studies. This significant facility will enable Hemogenyx Pharmaceuticals to move our life-saving technologies forward rapidly, placing the Company in a highly competitive position in the treatment of cancer and viral diseases."

Use of proceeds

The Facility will allow the Company to bring even greater focus to bear on scientific and commercial advances. The funds will enhance Hemogenyx Pharmaceuticals' control over its intellectual property assets under development and give it greater choice in determining what strategic partnerships to pursue and on what terms, enabling it to achieve maximum shareholder value.

Hemogenyx Pharmaceuticals has been successfully progressing in its development of its CDX antibody candidate ("CDX") and its HEMO-CAR-T product candidate. In addition, the Company has carried out considerable preliminary work on the development of its cell therapy platform as a novel means to allow the programming of immune cells to target both viral infections, including COVID-19, and certain types of cancer.

The Company intends to use the net proceeds of the issue of the Convertible Loan Notes to accelerate the development and marketability of its product candidates as follows:

Achieve clinical proof of concept for the Company's CDX bi-specific antibody product candidate if and when needed, including:
completing Investigative New Drug ("IND")-enabling pre-clinical studies that are needed in order to file an IND application requesting authorisation from the Food and Drug Administration ("FDA") or other applicable regulatory body to initiate clinical trials and administer the Company's CDX bi-specific antibody to humans;
filing an IND; and
completing Phase I/IIa clinical studies aimed at achieving clinical proof of concept and advancing the CDX bi-specific antibody toward later stages of clinical trials including Phase II and Phase III.
Achieve clinical proof of concept for the HEMO-CAR-T, including:
completing IND-enabling pre-clinical studies in collaboration with the University of Pennsylvania ("Penn");
filing an IND; and
completing Phase I/IIa clinical studies aimed at achieving clinical proof of concept and advancing HEMO-CAR-T towards later stages of clinical trials including Phase II and Phase III.
Achieve pre-clinical and clinical proof of concept for the Company's cell therapy platform (referred to by the Company as "CBR"), including:
completing the development and validation of CBR as a novel platform that allows the programming of immune cells to target either viral infections or certain types of cancer;
completing IND-enabling pre-clinical studies of an undisclosed CBR-based product candidate;
filing an IND; and
completing Phase I/IIa clinical studies aimed at achieving clinical proof of concept and advancing the undisclosed CBR-based product candidate toward later stages of clinical trials including Phase II and Phase III.
General working capital purposes

Current trading update

CDX Antibodies

Work with a global international pharmaceutical company ("GlobalCo") on the Company's CDX antibody ("CDX") as a clinical candidate, first announced on 14 May 2018, has entered its final phase. The term of the collaboration has been extended twice. The second extension announced on October 27, 2020 runs through the end of 2020. Both extensions were necessary to compensate for the slow down caused by the COVID-19 pandemic. The Company and GlobalCo continue to develop CDX toward clinical readiness and have nearly completed the manufacturability assessment and follow-up tests on the antibody.

Hemogenyx Pharmaceuticals and GlobalCo remain optimistic as to the outcome of these tests based on results to date and look forward to the completion of the scientific development work portion of the collaboration.

CAR-T Agreement with University of Pennsylvania

Hemogenyx Pharmaceuticals entered into a Sponsored Research Agreement ("Research Agreement") with the University of Pennsylvania, as announced on August 11, 2020. The goal of the Research Agreement is to advance the Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") developed by the Company toward clinical trials. The Research Agreement is envisaged as the first step of a larger program that aims to achieve clinical proof of concept for HEMO-CAR-T for the treatment of acute myeloid leukaemia ("AML").

The Company is pleased with the progress made to date under the terms of the Research Agreement.

CBR platform

As announced on April 22, 2020, the Company commenced development of a novel treatment for patients suffering from COVID-19. Recognising that the field was saturated with companies competing to develop clinical grade neutralising antibodies to treat COVID-19, the Company demonstrated its expertise and nimbleness, deploying its ingenuity and existing technologies, including its Advanced peripheral blood Hematopoietic Chimera ("ApbHC") (humanised mice), as well as its experience in programming immune cells, to develop a unique approach to combating viral infectious diseases more generally. As a result, the Company has developed a cell therapy platform, which it is calling CBR. The essence of CBR is the programming of immune cells using a novel type of modifiable synthetic receptor to destroy viral pathogens including SARS-CoV-2 which causes COVID-19. Not only can this type of synthetic receptor potentially combat viral pathogens, it can also potentially be modified to program immune cells to destroy malignant cells causing cancer. The novel synthetic receptor has no connection to, and does not resemble, any known or widely used Chimeric Antigen Receptors (CARs, e.g., HEMO-CAR-T), and the Directors are not aware of any direct competitor for this product candidate at this time. Hemogenyx Pharmaceuticals is engaged in pre-clinical validation of two CBR-based potential product candidates: one for the treatment of COVID-19, and the other for the treatment of an undisclosed type of cancer.

Further details of the Convertible Loan Notes

Mint Capital has conditionally agreed to subscribe for up to £60 million in aggregate principal amount of the Convertible Loan Notes pursuant to an agreement entered into today with the Company (the "Subscription Agreement"). The key terms of the Convertible Loan Notes include:

A principal amount of up to £60,000,000, split into denominations of £50,000 per Convertible Loan Note. The Convertible Loan Notes will be subscribed for at par.
The Convertible Loan Notes are to be issued in up to nine tranches. The first tranche of £12,000,000 in principal amount is expected to be issued immediately following satisfaction of the conditions in the Subscription Agreement (the "Initial Issue Date"). The subsequent eight tranches are issuable at the sole discretion of, and in the amounts determined by, the Company at respective intervals of 90 days after the Initial Issue Date. The aggregate maximum principal amount of the Convertible Loan Notes is limited to £60,000,000.
No interest is payable on the Convertible Loan Notes.
The Convertible Loan Notes are unsecured.
Each tranche of Convertible Loan Notes issued is redeemable at par on the date falling 36 months after the relevant Issue Date (the "Maturity Date").
Each of the Convertible Loan Notes is convertible into ordinary shares of £0.01 (1 pence) each in the capital of the Company ("Ordinary Shares") at any time during the period commencing on the fifth business day following the relevant Issue Date and ending at 5.00 p.m. London time on the business day immediately prior to the relevant Maturity Date (the "Conversion Period").
The price used for the conversion (the "Conversion Price") will be equal to a 10 per cent. discount to the lesser of (i) 125 per cent. of the closing-bid price as reported by Bloomberg for one Ordinary Share one trading day before the relevant Issue Date (subject to adjustment to reflect any sub-division or consolidation of the Ordinary Shares) and (ii) the lowest closing bid-price as reported by Bloomberg for an Ordinary Share from the three consecutive trading days ending on the day prior to the date of service of the relevant conversion notice (or if such conversion notice is served after 4.35pm on any such date, then the three consecutive trading days ending on the day such conversion notice is served. In no event shall the Conversion Price be less than the nominal value of an Ordinary Share.
A holder will not be permitted to submit a conversion notice in respect of the Convertible Loan Notes if the total Ordinary Shares held by the holder following the execution of such conversion notice would exceed 29.9 per cent. of the Company's total Ordinary Shares.
Subject to limited exceptions, the Convertible Loan Notes will not be transferable.
Prior to conversion, the Convertible Loan Notes do not entitle the holder to any voting rights in the Company.

Arrangement fee

The Company has agreed to pay a fee of five per cent. of the aggregate principal value of the Convertible Loan Notes issued to the arranger for the Facility (the "Arranger"). Such fee shall be payable by the allotment and issue of new Ordinary Shares, subject to the Directors having the necessary shareholder authorities in place to issue such new Ordinary Shares and the issue of new Ordinary Shares not requiring the publication of a prospectus by the Company. If such fee cannot be satisfied by the allotment and issue of new Ordinary Shares, it shall be paid in cash.

Circular and notice of General Meeting

The issue of the Convertible Loan Notes is subject to, amongst other things, the Company obtaining shareholder approval to grant the Directors the necessary authorities to issue the Convertible Loan Notes. A circular will be sent to the Company's shareholders in due course containing details of the Convertible Loan Notes and to convene a general meeting at which these approvals will be sought.

Other conditions to issue of the Convertible Loan Notes

The issue of Convertible Loan Notes on the Initial Issue Date is conditional on publication by the Company of a prospectus that has been approved by the FCA in respect of the admission of the Ordinary Shares to be issued on conversion of the Convertible Loan Notes to the standard segment of the Official List and to trading on the London Stock Exchange's main market for listed securities. The issue of Convertible Loan Notes on any issue date after the Initial Issue Date is conditional on that prospectus remaining valid or a further prospectus having been published by the Company.

The issue of the Convertible Loan Notes is also conditional upon the Subscription Agreement having become unconditional in all respects in respect of that relevant tranche of Convertible Loan Notes.

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, the person responsible for arranging for the release of this Announcement on behalf of the Company is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.

Enquiries:

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukaemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anaemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

Important Notice

This Announcement and the information contained in it is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or from any jurisdiction in which the same would constitute a violation of the relevant laws or regulations of that jurisdiction. No public offering of Convertible Loan Notes is being made in any jurisdiction. The distribution of this Announcement and the offering of the Convertible Loan Notes in certain jurisdictions may be restricted by law. No action has been taken by the Company that would permit an offering of the Convertible Loan Notes or possession or distribution of this Announcement or any other offering or publicity material relating to such Convertible Loan Notes in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company to inform themselves about, and to observe, such restrictions.

There are matters set out within this Announcement that are forward-looking statements. Such statements are only predictions, and actual events or results may differ materially. For a discussion of important factors which could cause actual results to differ from forward-looking statements, refer to the Company's Annual Report and Accounts for the period ended 31 December 2019. The Company does not undertake any obligation to update publicly, or revise, forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Announcement. No statement in this Announcement is or is intended to be a profit forecast or profit estimate or to imply that the earnings of the Company for the current or future financial periods will necessarily match or exceed the historical or published earnings of the Company. The price of Ordinary Shares and the income from them may go down as well as up and investors may not get back the full amount invested on disposal of the Ordinary Shares.

It is not expected that any Convertible Loan Notes will be admitted to trading on any stock exchange. This Announcement is not an offering document, prospectus, prospectus equivalent document.

Neither the content of the Company's website nor any links on the Company's website is incorporated in, or forms part of, this Announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

ReleaseID: 617283

BOCA RATON, FL / ACCESSWIRE / November 18, 2020 / Xeriant, Inc. (OTC PINK:XERI), a new aerospace technology holding company, announced today that an additional utility patent has been issued by the U.S. Patent and Trademark Office related to its Halo aircraft technology, strengthening its October 2019 patent. Both utility patents are retroactive to Halo's original 2007 continuation patent application date, and therefore have the benefit of preceding numerous drone or UAV (unmanned aerial vehicle) patent filings and claims.

Halo is a development-stage eVTOL (electric vertical takeoff and landing) powered lift aircraft that has been designed to seamlessly transition from vertical to forward flight by altering the direction of its propulsive thrust by approximately 90 degrees. Powered lift aircraft combine the VTOL capability and small logistical footprint of helicopters with the cruise speed, fuel efficiency and range of conventional fixed wing airplanes. Halo's unique and scalable tiltwing configuration, which features a pivoting cylindrical wing structure and a central axle-mounted payload area, can also accommodate a range of propulsion systems, including ducted lift fans and distributed electric rotors, as well as various stability and control systems.

When fully developed, Xeriant plans to introduce the innovative Halo platform as a small high-performance UAV for commercial applications such as inspections, surveying, surveillance, delivery and imagery, which is expected to compete favorably with other eVTOL UAV aircraft in terms of speed, acoustics, payload, maneuverability, efficiency, range and safety. Depending on the success of the small UAV model, Xeriant may begin to develop a larger scale Halo aircraft model for the emerging UAM (urban air mobility) market or a variant for military applications. UAM, which is part of advanced air mobility, refers to on-demand passenger or cargo transport in congested environments.

Halo was chosen to be a finalist presenter, out of approximately 70 companies, at the November 2019 Florida Aerospace Capital Forum.

"UAVs represent one of the most dynamic growth sectors in aerospace, with applications expanding into almost every industry. Empowered by innovation, these new aerial vehicles promise to make aviation a greater part of our daily lives. The additional patent protection on the Halo technology supports our efforts to establish a strong position in this space," stated Xeriant CEO, Keith Duffy.

Read this and more news for Xeriant and Halo at: www.xeriant.com and www.xeriant.com/about/halo-aircraft

ABOUT XERIANT

Xeriant, Inc. (d.b.a. Xeriant Aerospace) is a holding and operating company focused on acquiring, developing, and commercializing revolutionary, eco-friendly technologies with applications in aerospace, including innovative aircraft concepts targeting emerging opportunities within the aviation industry. In 2019, Xeriant acquired a unique, scalable, multi-purpose VTOL aerial platform called Halo, which is protected under a broad utility patent. Xeriant is located at the Research Park at Florida Atlantic University in Boca Raton, Florida adjacent to the Boca Raton Airport. The Company is an OTC Markets public company trading under the stock symbol, XERI.

SAFE HARBOR FORWARD-LOOKING STATEMENTS

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Xeriant, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations concerning our ability to attract investors.

We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

XERIANT, INC. CORPORATE

Keith Duffy, CEO
Innovation Centre #1
3998 FAU Blvd., Suite 309
Boca Raton, FL 33431
561-491-9595
corporate@xeriant.com
www.xeriant.com

SOURCE: Xeriant, Inc.

ReleaseID: 616611

HOUSTON, TX / ACCESSWIRE / November 18, 2020 / Memgen, a private biotechnology company developing novel treatments for cancer and COVID-19, today announced that John Poulos has joined the company's Board of Directors.

"I am very pleased to join the board of Memgen at this transformational time in the company's life," noted Mr. Poulos. "Memgen's strong and differentiated science hold promise both for patients with cancer and for an approach to COVID-19 that should be complementary to other approaches to vaccination. I look forward to helping the leadership team move these important treatments forward for the benefit of patients."

Dr. Gregory Brown, Memgen's CEO, also noted, "We are delighted to have John bring his extraordinary breadth of background and deep pharmaceutical expertise to bear as a member of Memgen's board. We are confident that John will add tremendous value as a director both in supporting the company's scientific progress and helping achieve positive business outcomes for the company."

Mr. Poulos has a wealth of expertise in global corporate life sciences, having spent 38 years working for AbbVie and Abbott. Mr. Poulos served as Vice President, Head of Business Development and Acquisitions for AbbVie from 2013 until his retirement in 2016. John was also Group Vice President, Head of Pharmaceutical Licensing and Acquisitions for Abbott from 2005 until 2012. During his career with AbbVie and Abbott, John was instrumental in the negotiation of numerous acquisitions, including Knoll/BASF Pharma in 2001 for $6.9 billion, Kos Pharmaceuticals in 2006 for $3.7 billion, Solvay in 2010 for $6.2 billion and Pharmacyclics in 2015 for $21 billion. He also has negotiated numerous partnerships and transactions which were instrumental in building the Abbott/AbbVie pharmaceutical portfolio.

Mr. Poulos is currently President of GNK Advisors, a business development consulting firm, and on the board of Faron Pharmaceuticals Oy. Mr. Poulos earned a bachelor's degree in marketing and an MBA in finance from Indiana University and was named the 2014 Frank Barnes Mentor Award recipient by the Licensing Executives Society.

About Memgen

Memgen is developing viral immunotherapies to harness the power of the immune system to cure cancer and to protect people from COVID-19 and other diseases. Its first-in-class immune-oncology therapeutics are designed for the treatment of patients who do not respond to currently available therapeutic options. The Company's lead cancer product, MEM-288, is engineered to both selectively target cancer cells and supercharge the immune system through expression of two unique and powerful immune modulators: CD40 ligand (CD40L) and the powerful cytokine interferon beta. MEM-288 has been demonstrated to generate a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. The Company expects to begin clinical testing with MEM-288 early in the coming year. Memgen's COVID-19 vaccine adjuvant, MemVax, is designed to be used with other vaccine technologies to generate a strong, durable immune response to protect against COVID-19 and other infectious diseases. The Company's pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already been tested in human subjects and has demonstrated the ability to elicit powerful, antigen-specific anti-tumor immune responses across a broad range of tumor types.

In this press release, unless the context requires otherwise, "Memgen," the "Company," "Companies," "we," "our," and "us" refers to Memgen, Inc.

Investor Contact:

Gregory B. Brown, M.D.
(203) 940-3742
gbrown@memgenbio.com

Media Contacts:

Gregory B. Brown, M.D.
(203) 940-3742
gbrown@memgenbio.com

SOURCE: Memgen

ReleaseID: 617140

From Pandemic Management to Vaccination Preparedness "We Can Supply That"

PORT WASHINGTON, NY / ACCESSWIRE / November 18, 2020 / Global Industrial, a value-added national distributor of industrial products and MRO supplies, a Systemax Inc. (NYSE:SYX) company, today announced the publication of its "Ready. Set. Vaccinate" guide to help healthcare facilities, pharmacies, doctor's offices and more, be prepared to administer COVID-19 vaccines when approved by the U.S. Food and Drug Administration or Health Canada.

Efficiently vaccinating the more than 360 million people in the United States and Canada, in a timely manner, is a monumental task. From procedures for managing patient flow, proper vaccine storage and handling, maintaining health and safety protocols for staff and patients, to medical waste disposal, there is a lot to think about. Transforming an existing portion of your facility or creating an outdoor clinic dedicated to administering vaccinations only adds to the planning process. For everyone involved, the time is now to plan, prepare and ready your facility.

"Throughout the pandemic, Global Industrial has been providing its business, government and educational customers with the support, solutions, and products to keep their facilities open and safe," said Barry Litwin, Chief Executive Officer of Systemax. "From room by room guides to address pandemic management, to the launch of our vaccination preparedness guide, we are providing the thought leadership to help customers proactively think through and successfully address the challenges they face."

"The recent announcement of two vaccines with efficacy rates of more than 90% is encouraging news in the fight against COVID-19. It is critical that everyone involved in the production, transfer, distribution, and administration of the vaccine be prepared. It is going to be a significant effort that will require the support and cooperation of everyone. At Global Industrial, we are proud to be in a position to help our customers get every American and Canadian safely through the vaccination process," concluded Litwin.

The "Ready. Set. Vaccinate" guide is designed to help businesses prepare their facilities for COVID-19 vaccinations. For more information about the "Ready. Set." program for your business, visit www.globalindustrial.com/readyset.

About Global Industrial
Global Industrial (www.globalindustrial.com) is a subsidiary of Systemax Inc. (NYSE: SYX). Global Industrial offers over 1.7 million industrial, material handling and business products for Fortune 1000 companies, small businesses, institutions and government agencies.

About Systemax Inc.
Systemax Inc. (www.systemax.com), through its operating subsidiaries, is a value added distributor of industrial products in North America going to market through a system of branded e-Commerce websites and relationship marketers. The primary brand is Global Industrial.

Forward-Looking Statement
This press release contains forward looking statements within the meaning of that term in the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Additional written or oral forward-looking statements may be made by Systemax Inc, the parent company of Global Industrial, from time to time in filings with the Securities and Exchange Commission or otherwise. Any such statements that are not historical facts are forward looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's estimates, assumptions and projections and are not guarantees of future performance.

Investor/Media Contact:
Mike Smargiassi
Ryan Golden
The Plunkett Group
212-739-6740
mike@theplunkettgroup.com
ryan@theplunkettgroup.com

SOURCE: Systemax via EQS Newswire

ReleaseID: 617197

VANCOUVER, BC / ACCESSWIRE / November 18, 2020 / Legend Power® Systems (TSXV:LPS) a global leader in commercial electrical system solutions, today announced that the Region of Peel in Ontario, Canada will invest in SmartGATE Platforms for four of its low-income multi-residential buildings.

After completing an initial pilot with Legend, the Region of Peel is now implementing SmartGATE as a standardized solution that can be deployed across their building portfolio to make achieving their sustainability targets easy. Over the anticipated lifespan of the solution these four sites are expected to save:

352 tons of carbon emissions
$900,000 of energy costs
8,100,000 kwh

Peel is known as a leader amongst their municipal peers, several of which in Ontario are investigating opportunities to deploy SmartGATE solutions within their portfolios.

Q4 F2020 Revenue Guidance
Based on preliminary results, the Company anticipates revenue for the three months ended September 30, 2020 to be between $350,000 and $400,000 compared with $485,543 in the same period of fiscal 2019. During Q4 of F2020, the Company's major markets began to reopen, and Q4 revenue guidance supports this assessment. Since quarter-end this momentum has continued across all geographies and end markets.

About SmartGATE
SmartGATE is an industry-leading, turnkey solution, which identifies and fixes underperformance and waste in the electrical system of a commercial building. These performance issues often impact key areas of commercial real estate metrics including occupant safety and satisfaction and financial performance. This waste can also lead to higher operating costs, lower net operating income and other potential financial risks to the building owner, including damaged tenant experience.

About Legend Power® Systems Inc.
Legend Power® Systems Inc. (www.legendpower.com) provides an intelligent energy management platform that analyzes and improves building energy challenges, significantly impacting asset management and corporate performance. Legend's proven solutions support proactive executive decision-making in a complex and volatile business and energy environment.

For further information, please contact:
Steve Vanry
CFO
+ 1 604 671 9522
svanry@legendpower.com

Sean Peasgood
Investor Relations
+ 1 647 503 1054
sean@sophiccapital.com

Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This Press Release may contain statements which constitute "forward-looking information", including statements regarding the plans, intentions, beliefs and current expectations of the Company, its directors, or its officers with respect to the future business activities and operating performance of the Company. The words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future business activities or performance and involve risks and uncertainties, and that the Company's future business activities may differ materially from those in the forward-looking statements as a result of various factors. Such risks, uncertainties and factors are described in the periodic filings with the Canadian securities regulatory authorities, including the Company's quarterly and annual Management's Discussion & Analysis, which may be viewed on SEDAR at www.sedar.com. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results to not be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update these forward-looking statements other than as may be required by applicable law.

SOURCE: Legend Power Systems Inc.

ReleaseID: 617264

Mining Complex Was Acquired for Its Asset Value in September of 2019 With Goal of Reclaiming Property and Moving Asset Base to Kentucky or Leasing Out to Third Party
Company Has Achieved Positive Environmental Results While Bolstering Its American Metals Business Line From the Property

FISHERS, IN / ACCESSWIRE / November 18, 2020 / American Resources Corporation (NASDAQ:AREC) ("American Resources" or the "Company"), a next-generation, socially responsible, supplier of raw materials to the new infrastructure market, today announced the move to fully reclaim the non-core Indiana thermal coal mine complex acquired from a bankruptcy in September 2019 for the complex's asset value given American Resources' operations focus on the steel, infrastructure and critical elements markets.

In 2019, the Company was approached by the trustee of a bankrupt estate on acquiring the facility. The management made the determination that based on the structures and asset value the property could be reclaimed for the future at a cost that would be lower than the acquired assets. Upon the closing of the asset acquisition, the Company has been reclaiming the over 175-acre property while also considering lease structures from third-party operators in the region. Based on current market conditions, American Resources has made the determination to continue with its primary plan to fully reclaim the site for the future and relocate certain assets to achieve a full bond release of approximately $1.3 million in environmental bonds.

Mark Jensen, Chairman and CEO of American Resources Corporation commented, "When approached by the estate's trustee, our team analyzed and determined that by utilizing an innovative and environmentally friendly approach, we could reclaim the property at a cost that was less than the asset value of the property and consideration paid as well as burning considerably less fuel. We also saw an opportunity to clean up the environmental liabilities that were neglected and egregiously left behind by the prior operators. When completed we are excited and confident that this project will prove that our model of achieving true social and environmental goals can be achieved while also generating a positive shareholder return to our investors."

Once taking ownership of the site, the Company, with collaborative efforts from its outsourced environmental solutions company Land Betterment Corporation, implemented a plan of action to clean up various environmental problems and bring the site back into compliance. Its innovative plan allowed them to balance the need for a sound reclamation plan alongside the need to do so in an efficient, environmentally-friendly manner which allowed its team to utilize a fraction of the fuel used in traditional "legacy" methods. To date, the Company has finished removing all structures out of the mine pit, removed a majority of the overland belt and a majority of mobile structures. The Company is now in the process of deconstructing and removing the processing facility, mobile stackers and coal load-out facility. American Resources will be accepting bids on the following items:

Processing plant components and/or modular structures within the processing plant

48-inch 120-foot rotary stacker

36-inch 100-foot rotary stacker

Power centers and other equipment

The Company, consistent with its forward-looking model, has recently announced that it has repurposed a segment of the acquired property for its American Metals business line to reprocess used coal railcars for the electric ARC furnace marketplace while also creating good-paying jobs in the community.

American Resources, since inception, has strategically acquired and restructured mining complexes to establish itself as one of the fastest-growing, lowest cost metallurgical carbon platforms in the Central Appalachian basin. Over the next few years, through cost-cutting and right-sizing operations, the Company has become one of the largest owners of mining infrastructure in eastern Kentucky. The Company is focused on utilizing its vast asset base to maximizing the value through its three core operating divisions:

American Carbon's production and processing of metallurgical carbon to the steel, specialty alloy metal and industrial marketplace.

American Metals' metal aggregation and processing market to the electric ARC furnace market.

American Rare Earth's critical elements production and processing business line providing the electric vehicle, permanent magnet and battery / battery storage marketplace.

About American Resources Corporation
American Resources Corporation is a supplier of high-quality raw materials to the rapidly growing global infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking. American Resources has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon deposits are concentrated.

American Resources has established a nimble, low-cost business model centered on growth, which provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure market while also continuing to acquire operations and significantly reduce their legacy industry risks. Its streamlined and efficient operations are able to maximize margins while reducing costs. For more information visit americanresourcescorp.com or connect with the Company on Facebook, Twitter, and LinkedIn.

Special Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond American Resources Corporation's control. The words "believes", "may", "will", "should", "would", "could", "continue", "seeks", "anticipates", "plans", "expects", "intends", "estimates", or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved.

PR Contact:
Precision Public Relations
Matt Sheldon
917-280-7329
matt@precisionpr.co

Investor Contact:
JTC Team, LLC
Jenene Thomas
833-475-8247
AREC@jtcir.com

Company Contact:
Mark LaVerghetta
317-855-9926 ext. 0
Vice President of Corporate Finance and Communications
investor@americanresourcescorp.com

SOURCE: American Resources Corporation

ReleaseID: 617232

BEVERLY HILLS, CA / ACCESSWIRE / November 18, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology is pleased to announce Michael Handelman, CPA has been appointed Chief Financial Officer of the Company.

Prior to joining the Company, Mr. Handelman served as Chief Financial Officer of Iovance Biotherapeutics, Inc. (IOVA), from February 2011 until June 2015 and was a member of the Iovance's Board of Directors from February 2013 until May 2013. Mr. Handelman became a Director of GoooGreen, Inc. in August 2020 and Chairman of the Board of Directors and Secretary in September 2020. He has served as Chief Financial Officer of Clickstream Corporation since October 2015. Mr. Handelman served as the Chief Financial Officer and as a financial management consultant of Oxis International, Inc., a public company engaged in the research, development and commercialization of nutraceutical products, from August 2009 until October 2011. From November 2004 to July 2009, Mr. Handelman served as Chief Financial Officer and Chief Operating Officer of TechnoConcepts, Inc., formerly a public company engaged in designing, developing, manufacturing and marketing wireless communications semiconductors, or microchips. Prior thereto, Mr. Handelman served from October 2002 to October 2004 as Chief Financial Officer of Interglobal Waste Management, Inc., a manufacturing company, and from July 1996 to July 1999 as Vice President and Chief Financial Officer of Janex International, Inc., a children's toy manufacturer. Mr. Handelman was also the Chief Financial Officer from 1993 to 1996 of the Los Angeles Kings, a National Hockey League franchise. Mr. Handelman is a certified public accountant, and holds a degree in accounting from the City University of New York.

Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented "Michael was CFO when I first created what is now known as Iovance Biotherapeutics, Inc. (IOVA). We are pleased to welcome Michael as our new CFO, and we look forward to working with Michael as we advance TriKE™ in clinical development for the treatment of cancer and other diseases."

About GTB-3550 Trispecific NK cell Engager (TriKE™)
GTB-3550 is the Company's first TriKE™ product candidate being initially developed for the treatment AML. GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The natural killer (NK) cell-stimulating cytokine human IL-15 portion of the molecule provides a self-sustaining signal that activates NK cells and enhances their ability to kill. We intend to study GTB-3550 in CD33 positive leukemias such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies.

About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary Tri-specific Killer Engager (TriKE™) platform. Our TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize cancer therapies using proprietary TriKE™ technologies.

Forward-Looking Statements
This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the fiscal year ended December 31, 2019 in the section titled "Risk Factors" in Part I, Item 1A and in our subsequent Form 10Q Quarterly filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.

Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

For more information, please visit www.gtbiopharma.com.

SOURCE: GT Biopharma, Inc.

ReleaseID: 617237

INCLINE VILLAGE, NV / ACCESSWIRE / November 18, 2020 / American Battery Metals Corporation (OTCQB:ABML) (the "Company"), an American-owned lithium-ion battery recycling technology and advanced extraction company with extensive mineral resources in Nevada, which is in the process of changing its name to American Battery Technology Company, is pleased to provide the following Company update.

American Battery Metals Corporation (soon to be re-named American Battery Technology Company "ABTC") is an industry leading clean technology innovator that has been created to increase the production of primary metals used in batteries that power electric cars, grid storage applications, and consumer electronics.

ABTC has built its capabilities to produce these battery metals through three business divisions: 1) recycling of lithium-ion batteries to recover battery metals, 2) extraction from primary resources, and 3) exploration of new primary resources. Together, the three approaches comprise a unique technologies platform that ensures battery metals are domestically sourced and re-used in an environmentally friendly, closed-loop fashion. ABTC's multi-pronged approach builds the foundation for a circular economy of battery metals that supports a global shift away from fossil fuel energy sources.

Our primary near-term objective is to escalate commercial application of our first-of-kind lithium-ion battery recycling and extraction capacities. Currently, we are:

Developing a physical pilot factory;
Expanding our technology and management team;
Positioning our technology platform for commercial deployment; and
Building strategic partnerships.

Expanding our team: ABTC has on-boarded key personnel in the areas of construction management, finance, logistics and chemical engineering to accelerate commercial deployment of our battery material extraction and recycling platform. Our leadership team has expanded with the promotion of Ryan Melsert to Chief Technology Officer and company Director and the hiring of Menka Sethi as Chief Operating Officer. David Corsaut has also joined ABTC as Chief Financial Officer, Scott Jolcover has joined as Chief Resource Officer, and David Batstone has joined as a company Director.

Market perspective: While the ABTC team has been hard at work operationalizing our innovative multi-pronged battery material recycling platform, the battery metals industry continues to grow significantly. Demand for lithium-ion batteries is predicted by industry researchers to skyrocket more than ten-fold over the next ten years. Over the same period, we anticipate limited announcements for new sources of U.S.-produced battery metals, including lithium, nickel, cobalt, and manganese. We expect increased pressure on prices of domestically sourced battery metals and an increased reliance on foreign sourced battery metals.

Pilot facility: This past year, ABTC purchased 12.44 acres in Fernley, Nevada to build a first of kind "green" battery recycling facility. The permitting process to open our state-of-the-art building is underway. Our Fernley facility will be designed to manage 20,000 metric tons of scrap materials and end-of-life batteries per year, representing approximately $160 million of annualized revenue and over 80% EBITDA at current commodity prices annually. To put this in context, currently only 90,000 metric tons of battery materials are recycled globally.

These exciting industry trends support and validate our business model to increase the production of domestic U.S. sourced battery metals. We look forward to continuing to grow our business as an industry leader in the closed loop production of the materials that fuel the new energy revolution.

About American Battery Metals Corporation

American Battery Technology Company is uniquely positioned to supply battery metals through its three divisions: lithium-ion battery recycling, extraction technology, and primary resources. The Company recently announced the groundbreaking of its lithium-ion battery recycling facility in Fernley, NV, and issued a recent shareholder letter outlining achievements of the past year.

American Battery Technology Company has built a clean technology platform that increases production of primary metals used in the batteries that power electric cars, grid storage applications, consumer electronics and tools. The green platform creates a circular economy for battery metals that champions ethical and environmentally sustainable sourcing of critical materials.[1]

For more information, please visit: www.americanbatterytechnology.com

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including those with respect to the expected project economics for Western Nevada Basin (Railroad Valley), including estimates of life of mine, average production, cash costs, AISC, initial CAPEX, sustaining CAPEX, pre-tax IRR, pre-tax NPV, net cash flows and recovery rates, the impact of self-mining versus contract mining, the timing to obtain necessary permits, the submission of the project for final investment approval and the timing of initial gold production after investment approval and full financing, metallurgy and processing expectations, the mineral resource estimate, expectations regarding the ability to expand the mineral resource through future drilling, ongoing work to be conducted at the Western Nevada Basin (Railroad Valley), and the potential results of such efforts, the potential commissioning of a Pre-Feasibility study and the effects on timing of the project, are "forward-looking statements." Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, interpretations or reinterpretations of geologic information, unfavorable exploration results, inability to obtain permits required for future exploration, development or production, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; fluctuating mineral and commodity prices, final investment approval and the ability to obtain necessary financing on acceptable terms or at all. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended September 30, 2019. The Company assumes no obligation to update any of the information contained or referenced in this press release.

Contact Information

p775-473-4744
info@batterymetals.com

SOURCE: American Battery Metals Corporation 

ReleaseID: 617266

– Interim DSMB review at the midpoint of the first dose cohort affirmed no safety or tolerability concerns with 75 mg of CRV431 in NASH patients –

– DSMB recommended the AMBITION study continue with 225 mg CRV431 dose cohort –

– Clinically significant reductions observed in the liver safety parameters ALT and AST –

EDISON, NJ / ACCESSWIRE / November 18, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that an independent Data Safety Monitoring Board ("DSMB") has approved the continuation of the company's Phase 2a ‘AMBITION' clinical trial to the next dose level cohort, after evaluating the safety and tolerability of the 75 mg CRV431 dose cohort in NASH patients. The study will now enroll NASH patients in the 225 mg dose cohort.

The AMBITION trial is the first placebo-controlled study of CRV431 in NASH patients with evidence of moderate-to-severe fibrosis. In this study, CRV431 is administered orally, once-daily for 28 days. The primary objectives of the trial are to assess safety and tolerability of CRV431, as well as to delineate pharmacokinetics. The secondary outcome measure of the trial is to evaluate decreases in non-invasive antifibrotic markers from baseline to the end of study. The study is being conducted at 10 sites in the U.S.

Dr. Stephen Harrison MD, Hepion's Consultant Medical Director, commented, "The DSMB review of the first CRV431 dose cohort in the Phase 2a AMBITION trial affirmed there were no safety or tolerability concerns. Moreover, when focusing on parameters of liver chemistry safety labs, reductions in ALT and AST were observed at Day 28. These data are very encouraging for the continued development of CRV431 as an oral, once-daily antifibrotic treatment for NASH patients."

"We are pleased with the DSMB's positive recommendation and look forward to continuing our AMBITION trial in NASH patients with moderate-to-severe fibrosis," commented Dr. Robert Foster PharmD, PhD, Hepion's CEO. "There are currently no approved treatments for NASH, which affects approximately 17 million people in the U.S. and may lead to cirrhosis, cancer, and death. This positive recommendation is an important advance for our company and in the quest to develop an orally active, once-daily, direct-acting antifibrotic to treat advanced NASH patients."

About Hepion Pharmaceuticals

Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company's lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431's potent inhibition of cyclophilins, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend," among others. These forward-looking statements are based on Hepion Pharmaceuticals' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com

SOURCE: Hepion Pharmaceuticals, Inc.

ReleaseID: 617286